Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Eleuthero (Eleutherococcus senticosus)

Plain-language summaryIntrigue 52 / 100

Eleuthero (Siberian ginseng, Eleutherococcus senticosus) is unrelated to true ginseng but shares similar adaptogenic properties. Eleutherosides drive the activity. Used historically by Soviet athletes and astronauts. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

22/100

Soviet-era adaptogen outpaced by modern alternatives on every dimension that matters for research

Look, Eleuthero has a real history. Brekhman’s Soviet-era research program in the 1960s and 1970s was a genuine scientific enterprise, conducted on cosmonauts and Olympic athletes with the goal of pharmacologically extending human stress tolerance. That work produced the adaptogen concept and Eleuthero was central to it. So we’re not dismissing this compound out of ignorance. We’re scoring it low because the research conversation has moved on, and what Eleuthero offers right now doesn’t justify prioritization over a crowded field that has lapped it in every measurable way.

The mechanism story is messy in ways that hurt research value. The active constituents, eleutherosides A through G, are structurally heterogeneous: some are syringaresinol diglucosides, others are sesamin glucosides, and they don’t share a clean pharmacological narrative. The adaptogen framing maps loosely onto HPA axis modulation, some NF-kB-adjacent effects, and plausible stress-pathway nudging, but theres no crisp target. That diffuseness is fine for a traditional supplement but frustrating as a research probe. You can’t ask a precise mechanistic question with a compound this heterogeneous and hope to isolate a clean signal.

The differentiation problem is the bigger issue. The adaptogen category has gotten dramatically more sophisticated since Brekhman’s era. KSM-66 ashwagandha now has multiple well-designed RCTs on cortisol, VO2max, and cognitive load. The SHR-5 rhodiola extract has replicated fatigue and cognitive signal in genuine double-blind designs. Schisandra work on NRF2 gives investigators a cleaner mechanistic handle than anything Eleuthero offers. Eleuthero doesn’t lead on any of these dimensions. If you’re building a research program around adaptogen biology, you reach for one of those alternatives first without a compelling reason not to.

The human evidence base doesn’t rescue the score. What exists is a combination of Soviet-era data (hard to verify, often not replicated outside the original research groups) and small Western trials that trend positive but are modest in effect size and inconsistent in standardization. Botanical variability in Eleutherococcus senticosus source material compounds this problem. Documented variation in eleutheroside content across commercial preparations makes cross-study comparison genuinely difficult and limits any meta-analytic signal.

We think of Eleuthero as an important historical artifact more than an active research target. Understanding its role in defining the adaptogen framework is worth doing for anyone entering that space. But as a compound you’d actively run experiments on today, theres a clear opportunity cost: your time and resources are better deployed against the adaptogens that have real modern RCT infrastructure, cleaner mechanistic stories, and extract standardization that actually holds up. Eleuthero’s decade was the 1970s, and it shows.

Novelty

12

Mechanism promise

22

In-category differentiation

18

Evidence quality

35

Translational signal

28

Research bench value

20

Rationale Eleuthero scores low across novelty and differentiation because it is a decades-old OTC herb with structurally heterogeneous constituents, a vague mechanism, and a human evidence base that hasn’t kept pace with rhodiola or ashwagandha. The raw weighted score of 22 sits comfortably below the OTC herb cap of 35, so no cap applies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Siberian ginseng adaptogen

A Siberian Eleutherococcus root extract historically classified as ‘ginseng’ but unrelated to Panax; characterized by eleutherosides with adaptogenic activity.

Abstract

Eleuthero (Eleutherococcus senticosus, formerly called Siberian ginseng) is a shrub root used in Russian and Chinese traditional medicine for fatigue, stress tolerance, and immune support. The active constituents are eleutherosides A through G, glycoside compounds with diverse structures (some are syringaresinol diglucosides, others are sesamin glucosides). The compound is structurally and pharmacologically distinct from Panax ginseng despite the historical “ginseng” naming. Russian research from the 1960s-1980s established the compound as an adaptogen with modest effects on physical and mental performance. The Western clinical evidence base is limited. Doses are typically 300 to 1200 mg standardized extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-114Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
CJC-1295 with DAC

Plain-language summaryIntrigue 65 / 100

CJC-1295 (with DAC) is the long-acting form of the GHRH analog. The DAC (drug affinity complex) binds to plasma albumin, extending the half-life from 30 minutes to about a week. Used in research for sustained growth hormone elevation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Albumin-binding GHRH analog

A long-acting GHRH analog with drug affinity complex (DAC) modification enabling weekly subcutaneous dosing through albumin binding.

Abstract

CJC-1295 with DAC (CJC-1295 long-acting; CAS 863288-34-0) is a modified GHRH 1-29 analog that incorporates a drug affinity complex (DAC) modification (a maleimidopropionyl-Lys side chain) which enables in vivo conjugation to circulating albumin through a covalent linkage with reduced cysteine 34. The albumin conjugation extends plasma half-life from minutes (for sermorelin) to approximately 6 to 8 days, enabling weekly subcutaneous dosing. The compound was developed by ConjuChem (Canada) and reached Phase 2 trials before being discontinued. The non-DAC version of CJC-1295 (without the albumin-binding modification) is the compound covered in our existing CJC-1295 nDAC monograph. The DAC version produces sustained mild GH and IGF-1 elevation rather than the pulsatile pattern of nDAC + GHRP combinations. Doses are 1 to 2 mg subcutaneously per week.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-131Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-DOPA (Levodopa)

Plain-language summaryIntrigue 80 / 100

L-DOPA (levodopa) is the immediate precursor to dopamine and the principal Parkinson disease treatment for over 50 years. It crosses the blood-brain barrier (which dopamine itself cannot) and is converted to dopamine by neuronal enzymes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

46/100

Gold-standard Parkinson’s workhorse with exceptional evidence but almost zero frontier research interest

Look, L-DOPA is about as well-understood as any molecule in clinical pharmacology. The biosynthesis pathway from tyrosine to DOPA to dopamine to norepinephrine has been in every biochemistry textbook since the 1960s, Arvid Carlsson shared a Nobel Prize in 2000 partly for mapping the dopamine deficiency story in Parkinson’s, and carbidopa co-formulation (Sinemet) has been optimized over five decades of clinical use. Thats not a criticism. Its just the reality of where the science stands.

The translational story is as complete as it gets. Multiple phase 3 trials, regulatory approval across essentially every major market, mechanistic confirmation in hundreds of independent labs. The ELLDOPA trial established dose-response relationships. Long-term studies have characterized the motor fluctuation and dyskinesia complications with precision. If what you want is evidence, L-DOPA has more of it than almost any compound in this library. If what you want is an unresolved scientific question to point your lab at, this isnt it.

Here’s where the research conversation actually lives today: continuous intestinal gel delivery systems (Duopa/Duodopa) for reducing off periods, subcutaneous levodopa infusion devices, alpha-synuclein aggregation as an upstream target, LRRK2 inhibition, gene therapy approaches that sidestep the precursor entirely. L-DOPA shows up in that research as a comparator arm or a background medication, not as the compound under investigation. Nobody is running a grant to ask whether L-DOPA works for dopamine-deficient Parkinson’s patients. That question is settled.

We think the bench value is modest but real in a narrow way. If you’re studying dopaminergic circuits, building PD animal models, or interrogating DOPA decarboxylase pharmacology, L-DOPA remains a useful and inexpensive tool. The Mucuna pruriens angle is occasionally cited in supplement literature but adds no meaningful research novelty. As a probe, it’s fine; as a target, there’s essentially nothing left to discover at the level a bench investigator could contribute.

The high evidence and translational scores prevent this from falling into the basement, and honestly that’s appropriate. L-DOPA is important and clinically indispensable. But the Kodiac library exists to surface what’s worth chasing next, and a fully-characterized approved drug that’s been in continuous use for sixty years scores exactly where the rubric puts it: respected, settled, and not the direction we’d point a serious research program.

Novelty

12

Mechanism promise

20

In-category differentiation

48

Evidence quality

88

Translational signal

85

Research bench value

45

Rationale L-DOPA earns high marks on evidence quality and translational signal because it is a definitively effective approved drug with decades of replication, but those same facts make it profoundly uninteresting as a research target: the mechanism is completely mapped, the compound is off-patent and commoditized, and the serious research conversation in dopaminergic biology has moved squarely to managing L-DOPA’s complications rather than L-DOPA itself. No hard cap binds; the raw weighted calculation lands the overall at 46.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dopamine precursor

The immediate precursor of dopamine and the principal pharmacological treatment for Parkinson disease, FDA-approved in combination with carbidopa.

Abstract

L-DOPA (levodopa, L-3,4-dihydroxyphenylalanine; CAS 59-92-7; molecular formula C9H11NO4; molecular weight 197.19) is the immediate precursor of dopamine in the catecholamine biosynthesis pathway. The compound is FDA-approved in combination with carbidopa (Sinemet) or benserazide for Parkinson disease. Carbidopa inhibits peripheral DOPA decarboxylase (which would otherwise convert most administered L-DOPA to dopamine before reaching CNS), enabling effective central dopamine elevation at lower doses with reduced peripheral adverse events. L-DOPA is the principal symptomatic treatment for Parkinson disease and remains the gold standard despite long-term complications including motor fluctuations and dyskinesia. The compound is also extracted naturally from Mucuna pruriens. Doses are highly individualized; typical Sinemet dosing is 25/100 mg three to four times daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-147Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Theobromine

Plain-language summaryIntrigue 45 / 100

Theobromine is the principal alkaloid of cocoa and chocolate. It is structurally similar to caffeine but with weaker stimulant effects and longer duration. The compound is highly toxic to dogs but not humans. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

26/100

Well-characterized food methylxanthine with narrow bench utility beyond the antitussive niche

Look, theobromine is chocolate’s primary methylxanthine, and that sentence basically tells you what you need to know about where it lands on a bench-research priority list. We’ve been studying this compound since the 1840s. Its pharmacology is almost entirely understood. It shares a mechanism class with caffeine (adenosine receptor antagonism, primarily A1 and A2A, plus phosphodiesterase inhibition) but with lower CNS potency and a more pronounced peripheral cardiovascular profile, specifically vasodilation and modest bronchodilation. That longer plasma half-life (7-12 hours versus caffeine’s 3-5 hours) does produce a meaningfully different pharmacokinetic signature, and thats worth noting for experimental design.

Where theobromine earns some genuine credit is in its antitussive biology. Peter Barnes’ group at Imperial College, along with independent replication in the early 2000s, showed that theobromine suppresses cough with efficacy comparable to low-dose codeine, mediated through a sensory nerve-desensitization pathway distinct from typical opioid mechanisms. The compound inhibits depolarization of capsaicin-sensitive vagal afferents at concentrations achievable in real experimental conditions. If you’re building a cough-reflex or airway-sensory research program, theobromine has more bench utility than you’d expect from a food compound, and it’s a cleaner probe here than theophylline.

Outside that niche, the research case is thin. The vasodilation signal is real but characterized to death. The CNS story is mostly “weaker caffeine,” which isn’t a story that motivates an investigator. Some labs have examined theobromine in combination with caffeine, and genuine synergistic interactions do appear, but isolating individual compound contributions is methodologically messy, and most combination literature arrives via industry-funded cocoa extract programs. Not great for drawing clean mechanistic conclusions.

What we dont see here is a novel mechanism, a fresh indication, or an underexplored compound with room for original contribution. The differentiation from caffeine is real but narrow: longer half-life, more peripheral, less central, and a legitimate antitussive probe angle. It’s not that the research is bad, it’s that the interesting questions have largely been answered. A bench investigator setting up a methylxanthine protocol would reach for caffeine or theophylline before theobromine unless that vagal sensory pathway is specifically on their agenda.

Sourcing is trivially easy, stability is fine, handling is unremarkable. None of that matters much when the science doesn’t reward the attention. This is library entry for reference completeness and the narrow antitussive comparison value, not a compound we’d prioritize for an active research program.

Novelty

12

Mechanism promise

18

In-category differentiation

28

Evidence quality

40

Translational signal

35

Research bench value

28

Rationale Novelty and mechanism scores are floored by decades of complete pharmacological characterization in a saturated compound class; a real but narrow antitussive signal from the Barnes group prevents complete dismissal but doesn’t rescue the overall score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylxanthine

The principal methylxanthine in cacao with milder CNS effects than caffeine and stronger peripheral vasodilation.

Abstract

Theobromine (3,7-dimethylxanthine; CAS 83-67-0) is the principal methylxanthine in cacao (Theobroma cacao), with smaller amounts in tea. The compound has milder CNS effects than caffeine but stronger peripheral cardiovascular effects (vasodilation, modest blood pressure reduction). Mechanism is the same general class as caffeine (adenosine antagonism, PDE inhibition) but with different relative potencies at the various adenosine receptor subtypes. Pharmacokinetics: plasma half-life 7 to 12 hours (longer than caffeine). Doses are typically 200 to 700 mg from supplements or chocolate. The compound is also notable for toxicity in dogs and other non-human mammals due to slower metabolism.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-163Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Curcumin

Plain-language summaryIntrigue 60 / 100

Curcumin is the principal polyphenol in turmeric. It has potent anti-inflammatory effects via NF-kB inhibition. Oral bioavailability is poor; formulations like phytosomal curcumin and BCM-95 substantially improve absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

27/100

Heavily studied polyphenol with assay-interference problems and weak translational record

Look, curcumin is probably the most studied compound that serious researchers have increasingly stopped trusting. The literature is enormous — tens of thousands of papers over five decades — and thats precisely the problem. A 2017 analysis formally classified curcumin as a PAIN compound (Pan-Assay INterference compound), documenting how it generates false-positive signals across a wide range of biochemical assays through non-specific mechanisms including autofluorescence, thiol reactivity, redox cycling, and metal chelation. A meaningful fraction of the curcumin in vitro signaling literature is artifactual, and the field has been slow to accept that.

The mechanism story reads well on paper: NF-kB inhibition, COX-2 modulation, JAK/STAT interference, Nrf2 activation, kinase targets all over the map. But “many targets” is another way of saying no clean mechanism. What you’re usually seeing is a promiscuous polyphenol interacting with assay components rather than selective engagement with any specific pathway. As a bench probe, curcumin fails the basic requirement of interpretable, reproducible results outside tightly controlled conditions.

The bioavailability situation is real and well-characterized. Free curcumin has oral bioavailability under one percent due to poor aqueous solubility, rapid glucuronidation and sulfation, and extensive first-pass clearance. Enhanced formulations — Meriva (phospholipid complex), Theracurmin (colloidal dispersion), Longvida (SLCP), BCM-95 (essential oil combination) — deliver 7- to 30-fold higher plasma exposure in human PK studies. We’re not dismissing those entirely; Meriva specifically has some legitimate joint-inflammation data from Indena-sponsored trials, and the bioavailability engineering story is at least mechanistically coherent. But effect sizes have been modest and the clinical program hasn’t produced anything that changes what a physician actually does.

Whats genuinely frustrating is the scale of resource investment versus yield. Phase 2 trials in colorectal cancer, IBD, Alzheimer’s disease, and type 2 diabetes have all been run. Results have been largely negative or underwhelming, and the failures are underrepresented in the published record. The registered trial database is more honest about the batting average than PubMed.

We think a serious bench investigator today would default to a more selective NF-kB probe, a cleaner COX-2 inhibitor, or a better-characterized Nrf2 activator before reaching for curcumin. The one legitimate use case is an investigator studying polyphenol pharmacokinetics directly, or validating a bioavailability enhancement platform, where curcumin’s extensive PK history and OTC status make it a convenient reference compound. Outside that narrow lane, the signal-to-noise ratio is genuinely poor and the compound deserves its declining place in serious research programs.

Novelty

18

Mechanism promise

28

In-category differentiation

22

Evidence quality

42

Translational signal

33

Research bench value

25

Rationale Curcumin scores low across novelty, mechanism, and differentiation due to decades-old, well-trodden chemistry and formal PAIN-compound status that undermines a significant fraction of the in vitro literature; the evidence base is enormous in volume but thin in quality, with most registered phase 2 clinical programs returning modest or negative results that rarely reach publication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Turmeric polyphenol

The principal yellow polyphenol of turmeric (Curcuma longa) with broad anti-inflammatory and antioxidant activity but very poor oral bioavailability without enhancement.

Abstract

Curcumin (CAS 458-37-7; molecular formula C21H20O6; molecular weight 368.38) is the principal yellow polyphenol pigment of turmeric (Curcuma longa) rhizome. The compound has broad anti-inflammatory activity (NF-kB inhibition, cyclooxygenase modulation, JAK/STAT modulation), antioxidant activity, and modulation of multiple cancer-related pathways. The principal limitation is poor oral bioavailability: free curcumin shows less than 1 percent oral bioavailability due to extensive first-pass metabolism. Bioavailability-enhanced formulations (Meriva, Theracurmin, Longvida, BCM-95) provide 7- to 30-fold higher plasma exposure and are required for meaningful systemic effects. Doses depend on formulation; standardized 95 percent curcuminoid powder at 1 to 3 grams per day is typical for non-enhanced; enhanced formulations use proportionally lower doses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-179Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lithium Carbonate (Low-Dose)

Plain-language summaryIntrigue 75 / 100

Lithium carbonate is the foundational mood stabilizer for bipolar disorder, in clinical use since the 1950s. At low doses (sometimes called microdose lithium, 1-5 mg) it is sometimes used for cognitive support; at standard psychiatric doses (600-1200 mg) it requires blood level monitoring. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

Mechanistically interesting GSK-3β probe held back by decades of inconclusive cognitive trial data

Look, lithium is one of the most mechanistically interesting old compounds in psychiatry, and the low-dose cognitive angle is worth understanding even if the overall picture is disappointing. The core mechanism story is solid: lithium inhibits GSK-3β at the magnesium-binding site, meaning it’s non-ATP-competitive and touches tau phosphorylation, Wnt signaling, and neurogenesis in ways that still matter for modern neurodegeneration research. The inositol monophosphatase axis adds a second real target. Two plausible links to Alzheimer’s pathology, both mechanistically grounded. That part we like.

The clinical record is where it falls apart. The LATTICE trial and most of the small MCI studies have come back with effect sizes barely distinguishable from noise. The epidemiological story is actually more interesting: populations with higher trace lithium in drinking water show lower dementia rates in multiple regional analyses from Europe, Japan, and Texas, but those associations are notoriously confounded and nobody has cleanly bridged from ecological correlation to individual-level causation in a powered RCT. The ALS signal, once moderately promising in preclinical models, largely failed to translate across the 2008-2013 trial wave. Thats a real problem for anyone trying to build a research program around the therapeutic case here.

Novelty is the compound’s biggest liability from a research-merit standpoint. Lithium has been in continuous clinical use since the late 1940s, GSK-3β inhibition has been known since the 1990s, and the low-dose cognitive angle has now generated enough inconclusive data that it’s neither fresh territory nor a solved question. It sits in an awkward middle: too old to be exciting, not resolved enough to be instructive. The literature is large but not convergent, and that’s genuinely frustrating.

What we do think is underappreciated is lithium’s bench value as a reference GSK-3β inhibitor. It’s still widely used in cell culture and organoid work precisely because it’s membrane-permeable, hits the target at low concentrations, and has known pharmacokinetics in virtually every model system. More selective inhibitors like CHIR99021 and SB216763 are now the standard where clean single-target readouts matter, but lithium remains useful when you want broad pathway context or need to compare against historical datasets. Its 75-year pharmacology dossier is actually a bench asset.

Honestly, the sourcing reality is fine and the safety profile at sub-therapeutic doses is better characterized than almost any research compound you’ll handle. But neither of those facts makes low-dose lithium more compelling as a primary research target in 2026. The renal and thyroid monitoring requirements add friction without adding signal, and we’re not optimistic that the next cognitive-indication trial cycle produces the clean positive that has eluded the field for two decades. Worth knowing well. Not worth centering a program on.

Novelty

35

Mechanism promise

55

In-category differentiation

42

Evidence quality

48

Translational signal

38

Research bench value

58

Rationale Lithium’s dual GSK-3β and inositol mechanisms are genuinely multi-target and relevant to tau biology, but the low-dose cognitive indication has failed to produce consistent clinical signal across multiple small RCTs, and novelty is severely constrained by 75 years of continuous clinical use. Bench value as a reference GSK-3β inhibitor keeps the score from collapsing further.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mood stabilizer (low-dose)

Prescription lithium carbonate at low doses (150-300 mg) studied for cognitive impairment and dementia prevention.

Abstract

Lithium carbonate (CAS 554-13-2) is the principal lithium salt used clinically since 1949 for bipolar disorder, with approved doses providing 600 to 1800 mg lithium ion per day for mood stabilization. Low-dose lithium (providing 150 to 300 mg lithium ion per day, well below therapeutic mood stabilization range) has been studied for cognitive impairment, Alzheimer disease, and ALS with mixed results; effect sizes are small but mechanistically interesting given lithium’s GSK-3 inhibition and inositol monophosphatase effects. Investigators using low-dose lithium should be aware of the still-narrow therapeutic index and potential renal and thyroid effects with chronic use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-195Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Trazodone

Plain-language summaryIntrigue 64 / 100

Trazodone is an old antidepressant from 1981 that almost nobody uses for depression anymore, because at the doses needed for mood (300 to 600 mg) it is unpleasantly sedating. What it gets prescribed for instead, by enormous margins, is sleep. At 25 to 100 mg it acts as a clean hypnotic by blocking the histamine receptor and the 5-HT2A serotonin receptor, both of which promote arousal. It is non-controlled, has no dependence potential, does not produce the next-day cognitive hangover of older sleep drugs, and is preferred for older adults specifically because it lacks the fall risk of benzodiazepines. The active leftover mCPP is a serotonin receptor activator that occasionally causes brief mood disturbance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

A 45-year-old approved hypnotic with one genuinely interesting neurodegeneration research angle that doesnt move the needle much

Look, trazodone is a compound thats easy to understand and hard to get excited about from a research frontier perspective. Approved by FDA in 1981, its been sitting in the formulary for over four decades as an antidepressant that nobody uses as a first-line antidepressant anymore. What it became is a sleep aid, and thats mostly because its 5-HT2A and H1 antagonism at low dose produces useful sedation without the dependency profile that comes with GABAergic hypnotics. That pharmacological angle is real, well-documented, and thoroughly exhausted as a research question.

The SARI mechanism itself is fine but unremarkable. The weak SERT inhibition (Ki around 160 nM) is why its not competitive with modern SSRIs. The H1 and 5-HT2A hit is why it works as a sleep agent. The active metabolite mCPP is a 5-HT2C agonist that explains some of the anxiogenic side effects some subjects report, and thats a mildly interesting pharmacological wrinkle but again not frontier territory. If you need a 5-HT2A antagonist tool compound, ketanserin is more selective and better characterized for that specific purpose.

Heres the one thing that keeps this from scoring lower than it does. In 2017 Mallucci’s group at the MRC Toxicology Unit published in Brain showing trazodone and dibenzoylmethane could restore protein synthesis in prion disease and other neurodegenerative models by activating eIF2B, essentially bypassing the phospho-eIF2alpha block in the integrated stress response. That finding was not trivial. The ISR pathway is a genuinely active research space for neurodegeneration, and trazodone turned out to be a tool compound for studying it. There’s been follow-up work and some early phase 2 signals in frontotemporal dementia. We think this is real biology. But the evidence base for this specific angle is still small, dominated by that group, and trazodone itself may not be the optimal probe for the ISR pathway going forward.

From a bench utility standpoint, trazodone sits in a weird middle space. Its too well-characterized to be interesting as a novel object of study, but its not indispensable as a research tool the way rapamycin is to mTOR work or ketamine is to NMDA biology. The hypnotic use case is settled science. The ISR angle is interesting but early and contested in terms of whether trazodone is the right vehicle to pursue that biology. What we dont like here is that a serious investigator studying either sleep pharmacology or the ISR pathway would almost certainly reach for different compounds first. The translational signal is solid because its an approved drug that demonstrably works, but that same approval status tells you the research questions around it were answered decades ago.

Novelty

18

Mechanism promise

35

In-category differentiation

28

Evidence quality

68

Translational signal

65

Research bench value

42

Rationale Trazodone scores well on translational signal and evidence because its an approved drug with a massive clinical base, but those same facts kill novelty and differentiation; the one legitimately interesting research angle (ISR/eIF2B activation in neurodegeneration, Mallucci group 2017 Nature) is intriguing but thin on replication and doesnt define a broader research program around trazodone specifically.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin antagonist and reuptake inhibitor (SARI)

A triazolopyridine antidepressant repurposed at low dose as a hypnotic via potent H1 and 5-HT2A antagonism.

Abstract

Trazodone (2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; CAS 19794-93-5; molecular formula C19H22ClN5O; molecular weight 371.86) is a triazolopyridine SARI developed at Angelini and approved by the FDA in 1981. The compound is a weak SERT inhibitor (Ki approximately 160 nM) but a potent 5-HT2A and H1 antagonist (5-HT2A Ki approximately 36 nM, H1 Ki approximately 220 nM). The active metabolite mCPP (m-chlorophenylpiperazine) is a 5-HT2C agonist contributing to anxiogenic side effects in some patients. Pharmacological profile distinguishes trazodone from SSRIs: at antidepressant doses (150 to 600 mg daily) the SERT inhibition contributes meaningfully, but at the more common hypnotic doses (25 to 100 mg) the H1 and 5-HT2A antagonism dominates, producing pronounced sedation without the GABAergic dependency profile of benzodiazepine hypnotics. Plasma half-life is bimodal: 3 to 6 hours alpha phase, 5 to 9 hours beta phase. Adverse events include orthostatic hypotension and the rare but serious priapism (1 in 1000 to 1 in 10000 incidence). Used as a low-dose hypnotic and as a reference compound for 5-HT2A receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-211Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tranylcypromine

Plain-language summaryIntrigue 65 / 100

Tranylcypromine (Parnate) is a first-generation MAOI from 1961 with a chemical backbone closely related to amphetamine. That structural quirk gives it a small but real direct stimulant component on top of the MAO inhibition, producing faster onset (1 to 2 weeks rather than the 4 to 6 weeks typical of MAOIs) and a more activating subjective profile than phenelzine. It carries the same dietary tyramine restrictions and drug interaction risks as the rest of its class. Like phenelzine it earns its place in the modern psychiatric armamentarium specifically for treatment-resistant depression cases where everything else has failed. The recent Tranylcypromine in Treatment-Resistant Depression literature has revived interest in disciplined modern use of these older drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Decades-old irreversible MAOI with real clinical history but negligible frontier research appeal

Look, tranylcypromine is a compound researchers already know. FDA-approved in 1961 under Parnate, it was the first non-hydrazine MAOI and carries a structurally unusual cyclopropylamine scaffold that bears a family resemblance to amphetamine. That amphetamine relationship is actually what makes it marginally more interesting than phenelzine on paper: in addition to irreversible MAO-A and MAO-B inhibition, it produces weak monoamine release, which probably explains the faster clinical onset (1 to 2 weeks versus 3 to 6 for phenelzine) and the mildly activating subjective profile investigators and clinicians have described for decades.

The mechanism, though, isnt novel. Irreversible non-selective MAO inhibition is 60-year-old pharmacology. The tyramine cheese effect is a textbook drug interaction. Plasma half-life is short (1.5 to 3.2 hours) but enzyme recovery is slow (5 to 10 days), which creates the dietary and drug-interaction burden that has made this class clinically awkward and commercially marginal since SSRIs came along. For a bench scientist, that interaction profile isnt interesting, its inconvenient background noise.

Where it retains real, if modest, value is as a reference compound. If your program is probing MAO biology, monoamine release, or you need a positive control in a dopaminergic assay, tranylcypromine is a well-characterized tool with known selectivity and a deep pharmacokinetic record. The (-)-trans isomer is the pharmacologically dominant form; the clinical preparation is racemic, which opens a stereochemistry question that’s occasionally been worth pursuing. And the cyclopropylamine scaffold itself has inspired structural analogs in newer programs, so investigators doing scaffold-level work sometimes keep it on the bench as a structural reference.

We dont think it belongs at the center of a serious research program right now. Treatment-resistant depression is genuinely interesting territory, and MAOIs are experiencing mild clinical rehabilitation in TRD discussions, but that reappraisal largely benefits phenelzine data and the class generally rather than generating new mechanistic questions specific to tranylcypromine. The frontier in TRD has moved toward ketamine, psychoplastogens, and the early GLP-1/neuroinflammation angle. If youre studying MAO biology specifically, selegiline gives you selective MAO-B inhibition for a cleaner dissection. If youre studying irreversible MAO-A, phenelzine has deeper clinical literature.

Tranylcypromine is a mature, approved drug with decades of human data. That means the evidence quality is better than most compounds in this library, and the translational signal is real. But research-merit scoring isnt about knowing a compound works. It’s about whether theres something left to discover. Here, the well is mostly dry.

Novelty

18

Mechanism promise

32

In-category differentiation

38

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Tranylcypromine scores low on novelty and mechanism because non-selective irreversible MAO inhibition is thoroughly mapped 1960s pharmacology, and the amphetamine-like dual mechanism is a curiosity rather than a research catalyst. Its bench value as a non-hydrazine MAOI reference compound and positive control in monoamine release assays keeps the overall from falling below the low forties, but theres no active frontier here.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-227Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lamotrigine

Plain-language summaryIntrigue 72 / 100

Lamotrigine (Lamictal) is a clean voltage-gated sodium channel blocker from GSK, approved by the FDA in 1994 for partial seizures and now equally important as a first-line mood stabilizer for bipolar depression and bipolar maintenance. It is unusual in mood medicine because, unlike lithium and valproate, it is more effective at preventing depressive episodes than manic ones. The mechanism is state-dependent: it preferentially binds inactivated sodium channels, which selectively dampens hyperactive neurons while leaving normal firing alone. The infamous risk is Stevens-Johnson syndrome (potentially fatal skin reaction) if titrated too quickly, which is why the dose-up schedule is conservative and stretched over weeks. Otherwise it is one of the most metabolically clean drugs in psychiatry. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

52/100

Mature VGSC blocker with uniquely differentiated bipolar depression profile and real but aging bench utility

Here’s the thing about lamotrigine: it’s one of the more mechanistically interesting anticonvulsants on paper, but it’s been around since 1994, and that age dominates the novelty picture. The core mechanism, state-dependent inhibition of voltage-gated sodium channels with preferential binding to the inactivated state, is thoroughly mapped. The downstream story, reduced presynaptic release of glutamate and aspartate, is well-understood. Secondary high-voltage-activated calcium channel inhibition and weak 5-HT3 antagonism add texture to the profile, but none of that is new territory for anyone working in this space.

What we actually find interesting about lamotrigine in a research context is the bipolar depression dissociation. Most mood stabilizers, lithium being the reference, are clearly better at suppressing mania than preventing depressive episodes. Lamotrigine inverts that relationship: the Calabrese et al. phase 3 maintenance datasets and the GSK registration trials established repeatedly that it’s primarily effective on the depressive pole. That asymmetry is real, replicated, and the mechanistic explanation for it remains genuinely open. If you’re studying the neuropharmacology of depression versus mania at the circuit or sodium channel isoform level, that gap is where the bench value lives.

As a pharmacological probe, lamotrigine is one of the cleaner VGSC tools available. Glucuronidation-dominated metabolism means fewer CYP2 interactions than carbamazepine or phenytoin, making it more tractable in multi-compound studies. For investigators working on glutamatergic excitability, firing-frequency-dependent channel pharmacology, or sodium channel isoform selectivity questions, its probe value is legitimate. It’s not indispensable in the way rapamycin is to mTOR work, but its clean metabolic profile and well-characterized kinetics make it useful in the right experimental context.

The honest constraint here is that theres not much frontier left. The mechanism is characterized to the point where a new bench scientist will find more questions answered than open. Clinical pharmacology is fully mapped. The rash and Stevens-Johnson liability, while manageable with slow titration in clinical settings, introduces real constraints in certain model systems. Patent expiry is ancient history. The compound does what it does very well, and the bipolar depression angle keeps it genuinely differentiated from lithium and valproate, but that differentiation is now a clinical fact rather than an active research question for most groups.

We score lamotrigine at 52: solidly useful in the right hands, genuinely differentiated on one clinical dimension, backed by strong evidence, but held back by age and thorough characterization. A researcher who specifically needs a state-dependent VGSC blocker or who is working on the bipolar depression mechanism question will find it indispensable. For general prioritization in a research library, it belongs in the catalog as a reference compound rather than a priority target.

Novelty

22

Mechanism promise

35

In-category differentiation

55

Evidence quality

82

Translational signal

78

Research bench value

58

Rationale Lamotrigine earns a mid-range score because the bipolar depression dissociation from the mania-dominant mood stabilizer class is genuinely differentiated and the evidence base is phase-3 strong; novelty and mechanism scores pull it down hard since the compound is fully characterized, decades off-patent, and there is no meaningful frontier science left in the core pharmacology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenyltriazine sodium channel blocker / mood stabilizer

A phenyltriazine voltage-gated sodium channel blocker; uniquely effective for bipolar depression and a first-line maintenance mood stabilizer.

Abstract

Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; CAS 84057-84-1; molecular formula C9H7Cl2N5; molecular weight 256.09) is a phenyltriazine voltage-gated sodium channel blocker developed at Wellcome (now GSK) and approved by the FDA in 1994 under the trade name Lamictal. Mechanism: state-dependent inhibition of voltage-gated sodium channels (preferentially binding inactivated state), reducing release of presynaptic glutamate and aspartate. Secondary inhibition of high-voltage-activated calcium channels and weak antagonism at 5-HT3 receptors contribute to the broader profile. Distinct among anticonvulsants for efficacy in bipolar depression and maintenance mood stabilization (more effective at preventing depressive than manic episodes, opposite the lithium pattern). Plasma half-life is 25 to 33 hours alone, shortened by enzyme-inducing comedications. Hepatic metabolism is primarily glucuronidation. The principal limitation is a benign rash incidence of approximately 10 percent and Stevens-Johnson syndrome at approximately 1 in 1000, both reduced by slow titration over 4 to 6 weeks. Approved for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and bipolar I disorder maintenance. Used as the reference anticonvulsant mood stabilizer and as a clean voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-243Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Guanfacine

Plain-language summaryIntrigue 62 / 100

Guanfacine is a more selective cousin of clonidine, originally a blood-pressure drug (Tenex) that found a second life as a non-stimulant ADHD medication (Intuniv, extended-release form). Where clonidine hits all three alpha-2 receptor subtypes broadly, guanfacine prefers the alpha-2A subtype, which is concentrated in the prefrontal cortex (the executive-function part of the brain). Activating it there appears to strengthen working memory and reduce impulsivity, which is the rationale for ADHD use. It is less sedating than clonidine at equivalent effect and is FDA-approved for ADHD in children and adolescents. Often combined with stimulants when stimulants alone are insufficient. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Canonical alpha-2A PFC probe with mature ADHD evidence; novelty is low, precision is high

Look, guanfacine is a genuinely useful compound and we’re glad it’s in the library, but let’s be honest about where it sits in the research landscape. This is a 1970s Sandoz molecule, FDA-approved for hypertension in 1986, with the ADHD indication following in 2009 as Intuniv. The core chemistry and pharmacology have been understood for decades, and there’s no mystery left in the primary mechanism.

What keeps it interesting is the alpha-2A subtype selectivity story. Clonidine predates guanfacine and acts across 2A, 2B, and 2C subtypes with less discrimination; guanfacine runs roughly 25-fold selective for 2A over the other subtypes. That matters because alpha-2A receptors dominate the prefrontal cortex, where adrenergic tone directly modulates working memory and executive function through post-synaptic signaling that reduces cAMP and increases the signal-to-noise ratio of PFC pyramidal neurons. Amy Arnsten’s work at Yale is the anchor here, and her group has done the most rigorous mapping of how alpha-2A agonism strengthens PFC network firing without the sedation you get from clonidine at comparable doses.

As a bench tool, guanfacine is the reference compound for alpha-2A pharmacology in the PFC. If you’re running experiments on stress-induced working memory impairment, age-related cognitive decline, or the adrenergic circuitry underlying impulsivity, guanfacine is your cleanest available probe. That’s a real point in its favor, and we score bench utility accordingly.

The evidence base is mature and solid. Multiple phase 3 RCTs in pediatric ADHD, a clean safety profile relative to stimulant alternatives, and well-replicated preclinical work in non-human primates and rodent models going back decades. That said, the effect sizes in ADHD are modest compared to stimulants, and the translational signal, while real and confirmed, doesnt represent a paradigm-defining clinical outcome. It’s a solid, confirmed, specific effect; not a revolutionary one.

We think the honest limitation here is novelty. There’s not much territory left to explore in the core mechanism. New applications do surface, including PTSD (guanfacine for hyperarousal, with some promising small trials out of groups like Pitman’s at Harvard) and emerging work on stress-sensitization in substance use disorders, and those angles give the score a small lift. But for most bench programs that dont specifically need an alpha-2A probe, guanfacine isnt the compound that’s going to define a new research direction. It does a specific job extremely well, and if that job is yours, it belongs in your toolkit.

Novelty

20

Mechanism promise

42

In-category differentiation

58

Evidence quality

73

Translational signal

67

Research bench value

63

Rationale Guanfacine earns on differentiation and evidence as the canonical alpha-2A selective agonist and an FDA-approved compound with replicated ADHD trials, but a 1970s mechanism and fully mapped pharmacology hold novelty and mechanism scores low, producing a mid-tier overall that reflects its value as a precision tool rather than a research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective alpha-2A adrenergic agonist

A selective alpha-2A adrenergic agonist; an antihypertensive repurposed as a non-stimulant ADHD treatment with greater alpha-2A selectivity than clonidine.

Abstract

Guanfacine (N-{[2-(2,6-dichlorophenyl)acetyl]amino}guanidine; CAS 29110-47-2; molecular formula C9H9Cl2N3O; molecular weight 246.10) is a selective alpha-2A adrenergic agonist developed at Sandoz in the 1970s and approved by the FDA in 1986 under the trade name Tenex (immediate release) and 2009 as Intuniv (extended release for ADHD). Distinct from clonidine by greater alpha-2A subtype selectivity (approximately 25-fold over alpha-2B and alpha-2C); the alpha-2A subtype predominates in the prefrontal cortex where it modulates working memory and executive function, supporting the cognitive enhancement seen in ADHD. The CNS-prefrontal cortex effect is more pronounced than the cardiovascular effect at clinical ADHD doses. Plasma half-life is approximately 17 hours, supporting once-daily dosing in the ER formulation. Renal excretion is the principal clearance pathway. Approved for hypertension and (Intuniv) ADHD in children and adolescents. Used as the canonical alpha-2A selective agonist in prefrontal cortex pharmacology and ADHD research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-259Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 60 61 62 63 64 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.